This Odd Little Kitty Turned Out To Be A New Species youtu.be/g8w43_QxKMk?...
This Odd Little Kitty Turned Out To Be A New Species
YouTube video by Animalogic
youtu.be
Kazuki Yoshida
@kaz-yos.bsky.social
Father in Training | #Rheumatology & Immunology Clinical Development | Pharmacoepidemiology | https://www.linkedin.com/in/kazyos/
You Speak Rheumatology!? www.linkedin.com/posts/nejm-g...
Dr. Glaucomflecken Explains: Secukinumab in Polymyalgia Rheumatica (REPLENISH) | NEJM Group
Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips. Glucocorticoids are the first-line treatment, but relapses and glucocorticoid-rel...
linkedin.com
Understandable explanation on the Hugging Face hack by OpenAI experimental agents m.youtube.com/watch?v=luXn...
The Doomsday Cult Inside OpenAI
YouTube video by Patrick Boyle
m.youtube.com
Novartis and Bristol Myers Squibb have paused their CAR-T trials for #lupus and other autoimmune diseases to review safety concerns. CAR-T remains experimental, and continued research is needed to understand its benefits and risks. Read the announcement: buff.ly/QJBbN7L
Lunar eclipse has began in New England. The photo is bad but the left lower corner is dark
I just found this strange structure on my corn. This turns out to be a male flower structure erroneously developing on a female flower structure (they are usually separated). www.farmprogress.com/corn/odd-sha...
Cell Therapy in Rheumatology: CAR-T vs Regulatory T Cells pca.st/episode/6f59... explore CAR-T therapy, immune resets, regulatory T cells, relapse risk, and the future of rheumatology with Dr. Georg Schett
ScienceInsider: HHS is now weighing in on science in NIH grants Staffers say comments coming after NIH’s own approvals are overriding peer review by Jocelyn Kaiser @jocelynkaiser.bsky.social @science.org bit.ly/4343TtT
FDA accepts Roche application for Gazyva/Gazyvaro in common lupus treatment | Seeking Alpha
FDA accepts Roche application for Gazyva/Gazyvaro in common lupus treatment
Roche’s Gazyva lupus FDA filing: B-cell anti-CD20 could be new SLE standard of care.
seekingalpha.com
Claude Code: This is indeed interesting. Claude examined the tableone codebase for TODO comments and implemented one of them. (I’m not going to merge this as it breaks backward compatibility)
‘If we’re not at the table, we’re on the menu’ FULL SPEECH: Canada’s PM Carney Says US-Led World Order Is Breaking at World Economic Forum | AC1G - YouTube www.youtube.com/watch?v=dTvF...
Your browser is up to date
You can use YouTube's latest features!
youtube.com
This is what happened in our neighborhood yesterday. ICE snatched a human being off of our streets, roughed them up badly, and then pepper sprayed legal observers as they documented it all. This is a daily occurrence happening all throughout Minnesota right now.
DMOAD has arrived!?: Biosplice Announces the Submission of its New Drug www.globenewswire.com/news-release...
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
Biosplice announces submission of new drug application to US FDA for treatment of knee osteoarthritis...
globenewswire.com
Marco Rubio is reportedly saying Maduro will stand trial in US courts. Which means it’s now the US administration’s position that US courts can hold foreign presidents, but not the US president, accountable for crimes.
The Wisconsin component of the analysis here is revealing. Evidence is consistent with DOGE strategically delaying contract terminations in WI until after the 2025 state Supreme Court elections to mitigate electoral risk.
John Holbein@johnholbein1.bsky.social · 10mo agoDOGE was A LOT less likely to cancel contracts from companies that donated money to Republicans than companies that donated to Democrats.
New Targeted Therapies for Sjögren’s Disease and Diagnostic Advances in 2025 | Vumedi
New Targeted Therapies for Sjögren’s Disease and Diagnostic Advances in 2025
A video from Robin Dore, posted on Dec 16, 2025.
vumedi.com
12 former commissioners of the FDA came together to write a Perspectives piece for the New England Journal of Medicine; raising our concerns about recent changes to vaccine approval policy at the FDA and its implications for patients and public health.
